Trial intelligence / Profile preview

TrasTUCAN Study

2024-512590-27-00Phase 2Completed

Sponsor: GEICAM
Start: Jun 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of trastuzumab, tucatinib and vinorelbine in breast cancer, sponsored by GEICAM. Primary endpoint: Objective response rate. Started Jun 2024; status: completed.

Drugs

trastuzumabtucatinibvinorelbine

Conditions

breast cancer

Beyond the preview

Go deeper on 2024-512590-27-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-512590-27-00.